Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease

UK Collaborative HIV Cohort CHIC S, L. Garvey*, A. Winston, J. Walsh, F. Post, K. Porter, B. Gazzard, M. Fisher, C. Leen, D. Pillay, T. Hill, M. Johnson, R. Gilson, J. Anderson, P. Easterbrook, L. Bansi, C. Orkin, J. Ainsworth, A. Palfreeman, M. GompelsA. N. Phillips, C. A. Sabin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objective: The impact of different antiretroviral agents on the risk of developing or surviving CNS disease remains unknown. The aim of this study was to investigate whether using antiretroviral regimens with higher CNS penetration effectiveness (CPE) scores was associated with reduced incidence of CNS disease and improved survival in the UK Collaborative HIV Cohort (CHIC) Study.

Methods: Adults without previous CNS disease, who commenced combination antiretroviral therapy (cART) between 1996 and 2008, were included (n = 22,356). Initial and most recent cART CPE scores were calculated. CNS diseases were HIV encephalopathy (HIVe), progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis (TOXO), and cryptococcal meningitis (CRYPTO). Incidence rates and overall survival were stratified by CPE score. A multivariable Poisson regression model was used to identify independent associations.

Results: The median (interquartile range) CPE score for initial cART regimen increased from 7 (5-8) in 1996-1997 to 9 (8-10) in 2000-2001 and subsequently declined to 6 (7-8) in 2006-2008. Differences in gender, HIV acquisition risk group, and ethnicity existed between CPE score strata. A total of 251 subjects were diagnosed with a CNS disease (HIVe 80; TOXO 59; CRYPTO 56; PML 54). CNS diseases occurred more frequently in subjects prescribed regimens with CPE scores = 10; however, these differences were nonsignificant. Initial and most recent cART CPE scores

Conclusion: Clinical status at time of commencing cART influences antiretroviral selection and CPE score. This information should be considered when utilizing CPE scores for retrospective analyses. Neurology (R) 2011; 76:693-700

Original languageEnglish
Pages (from-to)693-700
Number of pages8
Issue number8
Publication statusPublished - 22 Feb 2011


  • Adult
  • Anti-HIV Agents
  • Antigens, CD4
  • Central Nervous System Diseases
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • HIV
  • HIV Infections
  • Humans
  • Male
  • Regression Analysis
  • Reproducibility of Results
  • Retrospective Studies
  • Sex Factors


Dive into the research topics of 'Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease'. Together they form a unique fingerprint.

Cite this